Compare CTSO & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTSO | CCEL |
|---|---|---|
| Founded | 1997 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5M | 29.6M |
| IPO Year | 2008 | 2022 |
| Metric | CTSO | CCEL |
|---|---|---|
| Price | $0.46 | $4.05 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $5.38 | N/A |
| AVG Volume (30 Days) | ★ 209.1K | 5.1K |
| Earning Date | 05-01-2026 | 04-14-2026 |
| Dividend Yield | N/A | ★ 4.26% |
| EPS Growth | ★ 65.79 | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | $22,503,908.00 | ★ $25,384,279.00 |
| Revenue This Year | $10.34 | N/A |
| Revenue Next Year | $22.41 | N/A |
| P/E Ratio | ★ N/A | $353.00 |
| Revenue Growth | ★ 48.53 | 9.76 |
| 52 Week Low | $0.37 | $2.72 |
| 52 Week High | $1.39 | $5.43 |
| Indicator | CTSO | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 45.56 | 60.68 |
| Support Level | $0.37 | $3.14 |
| Resistance Level | $0.72 | $4.04 |
| Average True Range (ATR) | 0.06 | 0.19 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 35.57 | 100.00 |
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.